

# A disrupted RNA editing balance mediated by ADARs (A in human hepatocellular carcinoma

Gut

63, 832-843

DOI: [10.1136/gutjnl-2012-304037](https://doi.org/10.1136/gutjnl-2012-304037)

Citation Report

#	ARTICLE	IF	CITATIONS
1	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2014, 211, 613-621.	4.2	97
2	Inosine in DNA and RNA. <i>Current Opinion in Genetics and Development</i> , 2014, 26, 116-123.	1.5	117
3	ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 865-868.	1.1	13
4	RNA-binding proteins as molecular links between cancer and neurodegeneration. <i>Biogerontology</i> , 2014, 15, 587-610.	2.0	45
5	Alternative splicing of human <i>NT5E</i> in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73). <i>Molecular Biology of the Cell</i> , 2014, 25, 4024-4033.	0.9	39
6	Editing liver tumours. <i>Gut</i> , 2014, 63, 709-710.	6.1	1
7	The emerging role of RNA and DNA editing in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 308-316.	3.3	26
8	Discovery of Novel Genes and Gene Isoforms by Integrating Transcriptomic and Proteomic Profiling from Mouse Liver. <i>Journal of Proteome Research</i> , 2014, 13, 2409-2419.	1.8	25
9	The RNA editing enzymes ADARs: mechanism of action and human disease. <i>Cell and Tissue Research</i> , 2014, 356, 527-532.	1.5	35
10	An RNA Editor, Adenosine Deaminase Acting on Double-Stranded RNA (ADAR1). <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 437-446.	0.5	59
11	The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. <i>Protein and Cell</i> , 2014, 5, 673-691.	4.8	141
12	Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR-125a and miR-10a expression. <i>Molecular Medicine Reports</i> , 2015, 12, 93-98.	1.1	16
13	New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins. <i>Biomolecules</i> , 2015, 5, 2338-2362.	1.8	66
15	RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing. <i>Cancer Letters</i> , 2015, 357, 510-519.	3.2	41
16	An RNA editing fingerprint of cancer stem cell reprogramming. <i>Journal of Translational Medicine</i> , 2015, 13, 52.	1.8	46
17	Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. <i>Hepatic Oncology</i> , 2015, 2, 79-93.	4.2	16
18	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	7.7	426
19	Functional and genetic deconstruction of the cellular origin in liver cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 653-667.	12.8	249

#	ARTICLE	IF	CITATIONS
20	ADAR1 Prevents Liver Injury from Inflammation and Suppresses Interferon Production in Hepatocytes. <i>American Journal of Pathology</i> , 2015, 185, 3224-3237.	1.9	41
21	Alternative applications for distinct RNA sequencing strategies. <i>Briefings in Bioinformatics</i> , 2015, 16, 629-639.	3.2	35
22	Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. <i>Genes</i> , 2016, 7, 129.	1.0	58
23	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. <i>Gastroenterology</i> , 2016, 151, 637-650.e10.	0.6	127
24	Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. <i>American Journal of Human Genetics</i> , 2016, 98, 709-727.	2.6	129
25	e23D: database and visualization of A-to-I RNA editing sites mapped to 3D protein structures. <i>Bioinformatics</i> , 2016, 32, 2213-2215.	1.8	5
26	Knockdown of p54nrb inhibits migration, invasion and TNF- $\alpha$ release of human acute monocytic leukemia THP1 cells. <i>Oncology Reports</i> , 2016, 35, 3742-3748.	1.2	10
27	A novel IGH@ gene rearrangement associated with CDKN2A/B deletion in young adult B-cell acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2016, 11, 2117-2122.	0.8	4
28	RNA2DNAalign: nucleotide resolution allele asymmetries through quantitative assessment of RNA and DNA paired sequencing data. <i>Nucleic Acids Research</i> , 2016, 44, e161-e161.	6.5	13
29	Association between targeted somatic mutation (TSM) signatures and HGS $\rightarrow$ Ca progression. <i>Cancer Medicine</i> , 2016, 5, 2629-2640.	1.3	18
30	Etiology and Pathogenesis of Hepatocellular Carcinoma: Epigenetic Mechanisms. , 2016, , 1-13.		0
31	Nucleotide modifications in messenger RNA and their role in development and disease. <i>Biochemical Society Transactions</i> , 2016, 44, 1385-1393.	1.6	32
32	Limit theorems for empirical R $\hat{A}$ nyi entropy and divergence with applications to molecular diversity analysis. <i>Test</i> , 2016, 25, 654-673.	0.7	5
33	Complex regulation of ADAR-mediated RNA-editing across tissues. <i>BMC Genomics</i> , 2016, 17, 61.	1.2	69
34	The Extent of mRNA Editing Is Limited in Chicken Liver and Adipose, but Impacted by Tissular Context, Genotype, Age, and Feeding as Exemplified with a Conserved Edited Site in COG3. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 321-335.	0.8	13
35	Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. <i>Experimental Hematology</i> , 2016, 44, 125-131.e11.	0.2	6
36	A-to-I editing of coding and non-coding RNAs by ADARs. <i>Nature Reviews Molecular Cell Biology</i> , 2016, 17, 83-96.	16.1	717
37	Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. <i>Oncogene</i> , 2016, 35, 4407-4413.	2.6	81

#	ARTICLE	IF	CITATIONS
38	<scp>RNA</scp> editing in acute myeloid leukaemia with normal karyotype. <i>British Journal of Haematology</i> , 2016, 173, 788-790.	1.2	3
39	Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets. <i>Molecular Genetics and Genomics</i> , 2016, 291, 1035-1051.	1.0	31
40	RNA Editing Modulates Human Hepatic Aryl Hydrocarbon Receptor Expression by Creating MicroRNA Recognition Sequence. <i>Journal of Biological Chemistry</i> , 2016, 291, 894-903.	1.6	43
41	ADAR-mediated messenger RNA Editing: Analysis at the proteome level. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 32-42.	0.2	0
42	A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 4873-4884.	1.6	83
43	ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma. <i>International Journal of Oncology</i> , 2017, 50, 622-630.	1.4	65
44	Mechanisms and implications of ADAR-mediated RNA editing in cancer. <i>Cancer Letters</i> , 2017, 411, 27-34.	3.2	30
45	In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic. <i>Drug Resistance Updates</i> , 2017, 32, 16-22.	6.5	17
46	RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers. <i>Tumor Biology</i> , 2017, 39, 101042831770000.	0.8	43
47	RNA editing is induced by type I interferon in esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770854.	0.8	10
48	Adenosine Deaminases That Act on RNA (ADARs). <i>The Enzymes</i> , 2017, 41, 215-268.	0.7	29
49	Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3171-e3171.	2.7	125
50	RNA Editing in Pathogenesis of Cancer. <i>Cancer Research</i> , 2017, 77, 3733-3739.	0.4	60
51	ADAR2 regulates RNA stability by modifying access of decay-promoting RNA-binding proteins. <i>Nucleic Acids Research</i> , 2017, 45, gkw1304.	6.5	34
52	An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer. <i>Nucleic Acids Research</i> , 2017, 45, 10436-10451.	6.5	50
53	ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 799.	1.8	21
54	Asymptotic Approaches to Discovering Cancer Genomic Signatures. <i>Handbook of Statistics</i> , 2017, , 23-36.	0.4	1
55	Editing inducer elements increases A-to-I editing efficiency in the mammalian transcriptome. <i>Genome Biology</i> , 2017, 18, 195.	3.8	33

#	ARTICLE	IF	CITATIONS
56	Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. <i>Genome Biology</i> , 2017, 18, 205.	3.8	161
57	Accurate identification of RNA editing sites from primitive sequence with deep neural networks. <i>Scientific Reports</i> , 2018, 8, 6005.	1.6	16
58	Regulatory RNA Editing Sites in Cancer: Prediction and Beyond. <i>EBioMedicine</i> , 2018, 27, 7-8.	2.7	3
59	The Secretion of miR-200s by a PKC $\zeta$ /ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer. <i>Cell Reports</i> , 2018, 23, 1178-1191.	2.9	53
60	Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 13-21.		24
61	ADARs and editing: The role of A-to-I RNA modification in cancer progression. <i>Seminars in Cell and Developmental Biology</i> , 2018, 29, 123-130.	2.3	80
62	The role of A-to-I RNA editing in cancer development. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 51-56.	1.5	67
63	Identification and validation of alternative splicing isoforms as novel biomarker candidates in hepatocellular carcinoma. <i>Oncology Reports</i> , 2018, 41, 1929-1937.	1.2	12
64	The Role of RNA Editing in Cancer Development and Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2018, 9, 762.	1.5	70
65	Organ-wide profiling in mouse reveals high editing levels of Filamin B mRNA in the musculoskeletal system. <i>RNA Biology</i> , 2018, 15, 877-885.	1.5	13
66	ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. <i>Biological Research</i> , 2018, 51, 36.	1.5	39
67	Hepatocellular carcinoma: Where are we in 2018?. <i>Current Problems in Surgery</i> , 2018, 55, 450-503.	0.6	2
68	Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. <i>Nucleic Acids Research</i> , 2018, 46, 7953-7969.	6.5	41
69	Detection and Application of RNA Editing in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1068, 159-170.	0.8	7
71	Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. <i>Blood</i> , 2018, 132, 1304-1317.	0.6	67
72	Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?. <i>International Immunopharmacology</i> , 2018, 63, 58-65.	1.7	13
73	Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 258.	1.7	104
74	CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 2602-2612.	1.1	23

#	ARTICLE	IF	CITATIONS
75	SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates. <i>Nucleic Acids Research</i> , 2018, 46, 7379-7395.	6.5	22
76	RAMP3 is a prognostic indicator of liver cancer and might reduce the adverse effect of TP53 mutation on survival. <i>Future Oncology</i> , 2018, 14, 2615-2625.	1.1	16
77	Transcriptogenomics identification and characterization of RNA editing sites in human primary monocytes using high-depth next generation sequencing data. <i>Genomics</i> , 2019, 111, 899-905.	1.3	7
78	Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 273.	1.8	23
79	Cancer theâ€RBPâ€™euticsâ€™RNA-binding proteins as therapeutic targets for cancer. , 2019, 203, 107390.		125
80	Toward Deep Learning Approaches for Learning Structure Motifs and Classifying Biological Sequences From RNA A-to-I Editing Events. <i>IEEE Access</i> , 2019, 7, 127464-127474.	2.6	4
81	<p>ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8547-8555.	0.9	14
82	The fusion landscape of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2019, 13, 1214-1225.	2.1	11
83	Genome-wide identification of RNA editing in seven porcine tissues by matched DNA and RNA high-throughput sequencing. <i>Journal of Animal Science and Biotechnology</i> , 2019, 10, 24.	2.1	17
84	Molecular model linking Th2 polarized M2 tumourâ€™associated macrophages with deaminaseâ€™mediated cancer progression mutation signatures. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12760.	1.3	28
85	Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries. <i>Nucleic Acids Research</i> , 2019, 47, e22-e22.	6.5	23
86	ADAR1 Editing and its Role in Cancer. <i>Genes</i> , 2019, 10, 12.	1.0	71
87	Editome Disease Knowledgebase (EDK): a curated knowledgebase of editome-disease associations in human. <i>Nucleic Acids Research</i> , 2019, 47, D78-D83.	6.5	28
88	TRPM2-AS promotes cancer cell proliferation through control of TAF15. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 120, 105683.	1.2	35
89	Bioinformatics approaches for deciphering the epitranscriptome: Recent progress and emerging topics. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1587-1604.	1.9	38
90	&lt;p&gt;MCM10 Acts as a Potential Prognostic Biomarker and Promotes Cell Proliferation in Hepatocellular Carcinoma: Integrated Bioinformatics Analysis and Experimental Validation&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 9609-9619.	0.9	8
91	Identification and Spatiotemporal Expression of Adenosine Deaminases Acting on RNA (ADAR) during Earthworm Regeneration: Its Possible Implication in Muscle Redifferentiation. <i>Biology</i> , 2020, 9, 448.	1.3	4
92	Genomic Identification of RNA Editing Through Integrating Omics Datasets and the Clinical Relevance in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 37.	1.3	8

#	ARTICLE	IF	CITATIONS
93	Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. <i>Science Advances</i> , 2020, 6, eaba5136.	4.7	29
94	Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. <i>Nature Communications</i> , 2020, 11, 799.	5.8	69
95	Aberrant Overexpression of RNA-Editing Enzyme ADAR1 Promotes the Progression of Endometriosis. <i>Reproductive Sciences</i> , 2020, 27, 575-584.	1.1	1
96	Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma. <i>Nucleic Acids Research</i> , 2020, 48, 4463-4479.	6.5	9
97	RNA modifications and cancer. <i>RNA Biology</i> , 2020, 17, 1560-1575.	1.5	93
98	Adenosine-to-inosine RNA editing in the immune system: friend or foe?. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2931-2948.	2.4	31
99	ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118716.	1.9	17
100	Systematic identification of A-to-I editing associated regulators from multiple human cancers. <i>Computers in Biology and Medicine</i> , 2020, 119, 103690.	3.9	1
101	RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2021, 74, 135-147.	1.8	41
102	ADARs, RNA editing and more in hematological malignancies. <i>Leukemia</i> , 2021, 35, 346-359.	3.3	10
103	Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 624034.	2.2	8
104	The effects of RNA editing in cancer tissue at different stages in carcinogenesis. <i>RNA Biology</i> , 2021, 18, 1-16.	1.5	15
105	A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects. <i>Frontiers in Oncology</i> , 2020, 10, 632187.	1.3	17
106	â€œ3Câ€•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.4	9
108	RNA Interference in Aquaculture: A Small Tool for Big Potential. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 4343-4355.	2.4	15
109	RNA A-to-I editing, environmental exposure, and human diseases. <i>Critical Reviews in Toxicology</i> , 2021, 51, 456-466.	1.9	6
110	Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer. <i>Molecular Therapy</i> , 2021, 29, 3258-3273.	3.7	13
111	Evolutionary driving forces of <sc>Aâ€•toâ€•I</sc> editing in metazoans. <i>Wiley Interdisciplinary Reviews RNA</i> , 2022, 13, e1666.	3.2	19

#	ARTICLE	IF	CITATIONS
112	Direct Immunodetection of Global A-to-I RNA Editing Activity with a Chemiluminescent Bioassay. <i>Angewandte Chemie</i> , 2021, 133, 17146-17154.	1.6	1
113	Direct Immunodetection of Global A-to-I RNA Editing Activity with a Chemiluminescent Bioassay. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17009-17017.	7.2	10
114	RNA editing affects cis-regulatory elements and predicts adverse cancer survival. <i>Cancer Medicine</i> , 2021, 10, 6114-6127.	1.3	5
115	<sc>RNA</sc> editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating <sc>CX3CR1</sc> fractalkine expression. <i>Drug Development Research</i> , 2022, 83, 328-338.	1.4	6
116	Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer. <i>British Journal of Pharmacology</i> , 2022, 179, 2868-2889.	2.7	19
117	The Importance of the Epi-Transcriptome in Translation Fidelity. <i>Non-coding RNA</i> , 2021, 7, 51.	1.3	6
118	Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 754709.	1.2	7
119	SBSA: an online service for somatic binding sequence annotation. <i>Nucleic Acids Research</i> , 2022, 50, e4-e4.	6.5	8
120	The Role of RNA Editing in the Immune Response. <i>Methods in Molecular Biology</i> , 2021, 2181, 287-307.	0.4	8
121	To protect and modify double-stranded RNA – the critical roles of ADARs in development, immunity and oncogenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2021, 56, 54-87.	2.3	28
122	AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	91
123	A mark of disease: how mRNA modifications shape genetic and acquired pathologies. <i>Rna</i> , 2021, 27, 367-389.	1.6	24
124	ADAR1 p110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression. <i>Medical Science Monitor</i> , 2019, 25, 1469-1479.	0.5	22
125	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. <i>PLoS ONE</i> , 2013, 8, e81922.	1.1	30
127	ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications. <i>Annals of Translational Medicine</i> , 2019, 7, 686-686.	0.7	13
128	Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma. <i>Current Genomics</i> , 2015, 15, 469-480.	0.7	21
129	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1274.	1.7	27
130	LOXL2 upregulates hypoxia-inducible factor-1 signaling through Snail-FBP1 axis in hepatocellular carcinoma cells. <i>Oncology Reports</i> , 2020, 43, 1641-1649.	1.2	8



#	ARTICLE	IF	CITATIONS
131	Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1077-1087.	1.3	22
132	Epitranscriptomics of cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 42-55.	0.9	23
133	Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. <i>PeerJ</i> , 2020, 8, e9755.	0.9	13
137	Etiology and Pathogenesis of Hepatocellular Carcinoma: Epigenetic Mechanisms. , 2017, , 3029-3040.		0
141	The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. <i>American Journal of Cancer Research</i> , 2020, 10, 148-163.	1.4	10
142	Pterostilbene ameliorates the disrupted Adars expression and improves liver fibrosis in DEN-induced liver injury in Wistar rats: A novel potential effect. <i>Gene</i> , 2022, 813, 146124.	1.0	3
144	Inosine and its methyl derivatives: Occurrence, biogenesis, and function in RNA. <i>Progress in Biophysics and Molecular Biology</i> , 2022, 169-170, 21-52.	1.4	12
145	6-Thioguanine incorporates into RNA and induces adenosine-to-inosine editing in acute lymphoblastic leukemia cells. <i>Chinese Chemical Letters</i> , 2023, 34, 107181.	4.8	13
146	The edited UPF1 is correlated with elevated asparagine synthetase in pancreatic ductal adenocarcinomas. <i>Molecular Biology Reports</i> , 2022, 49, 3713-3720.	1.0	2
147	The Role of COL22A1 in the Pathophysiology of Hepatocellular Carcinoma: Evidence from Bioinformatics Exploration. <i>Cancer Management and Research</i> , 0, Volume 14, 739-750.	0.9	0
149	Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion. <i>Molecular Cancer Research</i> , 2022, 20, 960-971.	1.5	8
150	Downregulated ADARB1 Facilitates Cell Proliferation, Invasion and has Effect on the Immune Regulation in Ovarian Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 792911.	2.0	6
151	Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 861439.	1.3	0
152	ADAR1 and its implications in cancer development and treatment. <i>Trends in Genetics</i> , 2022, 38, 821-830.	2.9	33
153	The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 237.	2.4	2
155	ADAR1 Prevents R-loop Accumulation-Driven ATR Pathway Activation in Ovarian Cancer. <i>Journal of Cancer</i> , 2022, 13, 2397-2412.	1.2	8
156	A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 906-917.	1.9	10
157	Reduction of A-to-I RNA editing in the failing human heart regulates formation of circular RNAs. <i>Basic Research in Cardiology</i> , 2022, 117, .	2.5	19

#	ARTICLE	IF	CITATIONS
160	CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies. <i>Oncogene</i> , 2022, 41, 4591-4605.	2.6	4
161	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. <i>Vacunas (English Edition)</i> , 2022, 23, 222-233.	0.3	0
162	Site-directed RNA editing by harnessing ADARs: advances and challenges. <i>Functional and Integrative Genomics</i> , 2022, 22, 1089-1103.	1.4	6
163	Metabolic Analysis of Nucleosides/Bases in the Urine and Serum of Patients with Alcohol-Associated Liver Disease. <i>Metabolites</i> , 2022, 12, 1187.	1.3	4
164	The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF- $\kappa$ B1 p105 to p50. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	2
165	The Novel Action of miR-193b-3p/CDK1 Signaling in HCC Proliferation and Migration: A Study Based on Bioinformatic Analysis and Experimental Investigation. <i>International Journal of Genomics</i> , 2022, 2022, 1-19.	0.8	1
166	Somatic A-to-I RNA Edited RHOA isoform 2 specific R176G mutation promotes tumor progression in lung adenocarcinoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	1
167	ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 Cells. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 4035-4047.	1.1	0
168	ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer. <i>Experimental and Molecular Medicine</i> , 2023, 55, 95-107.	3.2	4
169	Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. <i>Nutrients</i> , 2023, 15, 121.	1.7	0
170	The Interplay between RNA Editing Regulator ADAR1 and Immune Environment in Colorectal Cancer. <i>Journal of Oncology</i> , 2023, 2023, 1-13.	0.6	4
171	Increased A-to-I RNA editing in atherosclerosis and cardiomyopathies. <i>PLoS Computational Biology</i> , 2023, 19, e1010923.	1.5	2
172	Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. <i>Cell Stem Cell</i> , 2023, 30, 250-263.e6.	5.2	10
173	Genome-wide identification of A-to-I RNA editing events provides the functional implications in PDAC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
175	The Allelic Expression of RNA Editing Gene ADARB1 in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 229-238.	0.4	0
183	RNA modification in cardiovascular disease: implications for therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	0
185	Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 143-179.	0.2	0